Literature DB >> 26917779

Rapid discrimination of the phenotypic variants of von Willebrand disease.

Jonathan C Roberts1, Patti A Morateck2, Pamela A Christopherson2, Ke Yan2, Raymond G Hoffmann2, Joan Cox Gill2, Robert R Montgomery2.   

Abstract

Approximately 20% to 25% of patients with von Willebrand disease (VWD) have a qualitative defect of the von Willebrand factor (VWF) protein activities. Variant VWD typically is classified as type 1C, 2A, 2B, 2M, or 2N depending on the VWF activity defect. Traditionally, diagnosis has relied on multiple clinical laboratory assays to assign VWD phenotype. We developed an enzyme-linked immunosorbent assay (ELISA) to measure the various activities of VWF on a single plate and evaluated 160 patient samples enrolled in the Zimmerman Program for the Molecular and Clinical Biology of von Willebrand Disease with type 2 VWD. Using linear discriminate analysis (LDA), this assay was able to identify type 1C, 2A, 2B, 2M, or 2N VWD with an overall accuracy of 92.5% in the patient study cohort. LDA jackknife analysis, a statistical resampling technique, identified variant VWD with an overall accuracy of 88.1%, which predicts the assay's performance in the general population. In addition, this assay demonstrated correlation with traditional clinical laboratory VWF assays. The VWF multiplex activity assay may be useful as a same-day screening assay when considering the diagnosis of variant VWD in an individual patient.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26917779      PMCID: PMC4874227          DOI: 10.1182/blood-2015-11-664680

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease--results based on an epidemiological investigation.

Authors:  F Rodeghiero; G Castaman; A Tosetto
Journal:  Thromb Haemost       Date:  1990-11-30       Impact factor: 5.249

2.  Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.

Authors:  G Castaman; J C Eikenboom; R M Bertina; F Rodeghiero
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

3.  The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.

Authors:  Giancarlo Castaman; Alberto Tosetto; Anne Goodeve; Augusto B Federici; Stefan Lethagen; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; David Habart; Frank Hill; Ian Peake; Francesco Rodeghiero
Journal:  Br J Haematol       Date:  2010-08-25       Impact factor: 6.998

4.  Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.

Authors:  C A Hillery; D J Mancuso; J Evan Sadler; J W Ponder; M A Jozwiak; P A Christopherson; J Cox Gill; J Paul Scott; R R Montgomery
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

5.  Relative value of diagnostic studies for von Willebrand disease.

Authors:  E J Werner; T C Abshire; D S Giroux; E L Tucker; E H Broxson
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

6.  Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.

Authors:  Emmanuel J Favaloro
Journal:  Thromb Haemost       Date:  2010-08-30       Impact factor: 5.249

7.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Authors:  Steve Kitchen; Ion Jennings; Tim A L Woods; Dianne P Kitchen; Isobel D Walker; Francis E Preston
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

8.  Prevalence of von Willebrand disease in children: a multiethnic study.

Authors:  E J Werner; E H Broxson; E L Tucker; D S Giroux; J Shults; T C Abshire
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

9.  A comparative evaluation of a new automated assay for von Willebrand factor activity.

Authors:  A S Lawrie; F Stufano; M T Canciani; I J Mackie; S J Machin; F Peyvandi
Journal:  Haemophilia       Date:  2012-12-04       Impact factor: 4.287

10.  Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.

Authors:  P A Kroner; K D Friedman; S A Fahs; J P Scott; R R Montgomery
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

View more
  4 in total

Review 1.  What have we learned from large population studies of von Willebrand disease?

Authors:  Robert R Montgomery; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.

Authors:  Jonathan C Roberts; Lynn M Malec; Imrran Halari; Sarah A Hale; Abiola Oladapo; Robert F Sidonio
Journal:  Haemophilia       Date:  2021-11-10       Impact factor: 4.263

3.  One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients.

Authors:  Nico C B de Jager; Laura H Bukkems; Jessica M Heijdra; Carolien H C A M Hazendonk; Karin Fijnvandraat; Karina Meijer; Jeroen Eikenboom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Marjon H Cnossen; Ron A A Mathôt
Journal:  J Thromb Haemost       Date:  2019-10-21       Impact factor: 5.824

4.  Sixth Åland Island Conference on von Willebrand disease.

Authors:  Erik Berntorp; Sonata S Trakymienė; Augusto B Federici; Katharina Holstein; Fernando F Corrales-Medina; Glenn F Pierce; Alok Srivastava; Mario von Depka Prondzinski; Jill M Johnsen; Irena P Zupan; Susan Halimeh; Vuokko Nummi; Jonathan C Roberts
Journal:  Haemophilia       Date:  2022-07       Impact factor: 4.263

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.